Abstract
Allelic alterations of chromosomes 1 and 19 are frequent events in human diffuse gliomas and have recently proven to be strong predictors of chemotherapeutic response and prolonged survival in oligodendrogliomas (Cairncross et al., 1998; Smith et al., submitted). Using 115 human diffuse gliomas, we localized regions of common allelic loss on chromosomes 1 and 19 and assessed the association of these deletion intervals with glioma histological subtypes. Further, we evaluated the capacity of multiple modalities to detect these alterations, including loss of heterozygosity (LOH), fluorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH). The correlation coefficients for detection of 1p and 19q alterations, respectively, between modalities were: 0.98 and 0.87 for LOH and FISH, 0.79 and 0.60 for LOH and CGH, and 0.79 and 0.53 for FISH and CGH. Minimal deletion regions were defined on 19q13.3 (D19S412-D19S596) and 1p (D1S468-D1S1612). Loss of the 1p36 region was found in 18% of astrocytomas (10/55) and in 73% (24/33) of oligodendrogliomas (P<0.0001), and loss of the 19q13.3 region was found in 38% (21/55) of astrocytomas and 73% (24/33) of oligodendrogliomas (P=0.0017). Loss of both regions was found in 11% (6/55) of astrocytomas and in 64% (21/33) of oligodendrogliomas (P<0.0001). All gliomas with LOH on either 1p or 19q demonstrated loss of the corresponding FISH probe, 1p36 or 19q13.3, suggesting not only locations of putative tumor suppressor genes, but also a simple assay for assessment of 1p and 19q alterations as diagnostic and prognostic markers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ashworth LK, Batzer MA, Brandriff B, Branscomb E, de Jong P, Garcia E, Garnes JA, Gordon LA, Lamerdin JE, Lennon G, Mohrenweiser H, Olsen AS, Slezak T and Carrano AV. . 1995 Nat. Genet. 11: 422–427.
Baer R. . 1993 Sem. Cancer Biol. 4: 341–347.
Bello MJ, Leone E, Vaquer J, De Campos JM, Kusak ME, Sarasa JL, Pestaña A and Rey JA. . 1995 Int. J. Cancer 64: 207–210.
Bello MJ, Vaquero J, De Campos JM, Kusak ME, Sarasa JL, Saez-Castresana J, Pestana A and Rey JA. . 1994 Int. J. Cancer 57: 172–175.
Cairncross JG and Macdonald DR. . 1988 Ann. Neurol. 23: 350–364.
Cairncross JG, Macdonald DR, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold Jr C, Wainman N and Eisenhauer E. . 1994 J. Clin. Oncol. 12: 2013–2021.
Cairncross JG, Ueki K, Zlatescu C, Lisle DK, Finkelstein DM, Hammond RR, Silver JR, Stark PC, Macdonald DR, Ino Y, Ramsay DA and Louis DN. . 1998 J. Natl. Cancer Inst. 90: 1473–1479.
Chung R, Whaley J, Kley N, Anderson K, Louis D, Menon A, Hettlich C, Freiman R, Hedley-Whyte ET, Martuza R, Jenkins R, Yandell D and Seizinger BR. . 1991 Genes Chrom. Cancer 3: 323–331.
Cliby W, Ritland SJ, Hartmann L, Dodson M, Halling KC, Keeney G, Podratz KC and Jenkins RB. . 1993 Cancer Res. 53: 2393–2398.
Cohen J. . 1960 Educ. Pschol. Meas. 20: 37–46.
Collins A, Keats BJ, Dracopoli N, Shields DC and Morton NE. . 1992 Proc. Natl. Acad. Sci. USA 89: 4598–4602.
Frankel RH, Bayona W, Koslow M and Newcomb EW. . 1992 Cancer Res. 52: 1427–1433.
Fults D, Brockmeyer D, Tullous MW, Pedone CA and Cawthon RM. . 1992 Cancer Res. 52: 674–679.
GDB(TM) Human Genome Database [database online] . Baltimore (Maryland, USA): Johns Hopkins University, 1990–Updated daily. Available from Internet: URLhttp://www.gdb.org/
Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D and Rattner RB. . 1992 J. Neurosurg. 76: 741–745.
Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW and Waldman FM. . 1994 Proc. Natl. Acad. Sci. USA 91: 2156–2160.
Kim DH, Mohapatra G, Bollen A, Waldman FM and Feuerstein BG. . 1995 Int. J. Cancer 60: 812–819.
Kim L, Hochberg FH, Thornton AF, Harsh GR, Patel H, Finkelstein D and Louis DN. . 1996 J. Neurosurg. 85: 602–607.
Kleihues P, Burger PC and Scheithauer BW. . 1992 Histological typing of tumours of the central nervous system. Springer-Verlag: Berlin.
Kraus JA, Koopman J, Kaskel P, Maintz D, Brandner S, Louis DN, Wiestler OD and von Deimling A. . 1995 J. Neuropathol. Exp. Neurol. 54: 91–95.
Levin VA, Gutin PH and Leibel S. . 1993 Cancer Principles and Practice of Oncology. De Vita Jr VT, Hellman S, Rosenberg SA . (eds). Lippincott: Philadelphia pp. 1679–1737.
Lindblom A, Skoog L, Rotstein S, Werelius B, Larsson C and Nordenskjöld M. . 1993 Cancer Res. 55: 4356–4361.
Louis DN. . 1997 Brain Pathol. 7: 755–764.
Louis DN and Gusella JF. . 1995 Trends in Genet. 10: 412–415.
Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, Stangl AP, Louis DN, Schramm J, Wiestler OD and von Deimling A. . 1997 J. Neuropathol. Exp. Neurol. 56: 1098–1104.
Mason WP, Krol GS and DeAngelis LM. . 1996 Neurology 46: 203–207.
Mohapatra G, Bollen AW, Dong HK, Lamborn K, Moore DH, Prados MD and Feuerstein BG. . 1998 Genes Chrom. Cancer 21: 195–206.
Mohapatra G, Kim DH and Feuerstein BG. . 1995 Genes Chrom. Cancer 13: 86–93.
Mullokandov MR, Kholodilov NG, Atkin NB, Burk RD, Johnson AB and Klinger HP. . 1996 Cancer Res. 56: 197–205.
Murray JC, Buetow KH, Weber JL, et al. 1994 Science 265: 2049–2054.
Nunnally J. . 1967 Psychometric Theory. McGraw-Hill: New York.
Perry A, Nobori T, Ru N, Anderl K, Borell TJ, Mohapatra G, Feuerstein BG, Jenkins RB and Carson DA. . 1997 J. Neuropathol Exp. Neurol. 56: 999–1008.
Piper J, Rutovitz D, Sudar D, Kallioniemi A, Kallioniemi O, Waldman FM, Gray JW and Pinkel D. . 1995 Cytometry 19: 10–26.
Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM and Jenkins RB. . 1995 Cancer Res. 55: 5408–5414.
Ransom DT, Ritland SR, Moertel CA, Dahl RJ, O'Fallon JR, Scheithauer BW, Kimmel DW, Kelly PJ, Olopade OI, Diaz MO and Jenkins RB. . 1992 Genes Chrom. Cancer 5: 357–374.
Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W and Collins VP. . 1994 Am. J. Pathol. 145: 1175–1190.
Ritland SR, Ganju V and Jenkins RB. . 1995 Genes Chrom. Cancer 12: 277–282.
Rosenberg JE, Lisle DK, Burwick JA, Ueki K, von Deimling A, Mohrenweiser HW and Louis DN. . 1996 Oncogene 13: 2483.
Saltman DL, Mellentin JD, Smith SD and Cleary ML. . 1990 Genes Chromsom. Cancer 2: 259–265.
Schwab M, Praml C and Amler LC. . 1996 Genes Chromsom. Cancer 16: 211–229.
Seizinger BR, Klinger HP, Junien C, Nakamura Y, Le Beau M, Cavanee W, Emanuel B, Ponder B, Naylor S, Mitelman F, Louis DN, Menon A, Newsham I, Decker J, Kaelbing I, Henry I and von Deimling A. . 1991 Cytogenet. Cell Genet. 58: 1080–1096.
Smith JS and Jenkins RB. . 1997 FASEB 11: A451:3131.
Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Smith SM, Kimmel D, Burger PC, Scheithauer BW and Jenkins RB . (submitted).
Testa JR, Siegfried JM, Liu Z, Hunt JD, Feder MM, Litwin S, Zhou J, Tagucji T and Keller SM. . 1994 Genes Chromosom. Cancer 11: 178–194.
Weber RG, Sabel M, Reifenberger J, Sommer C, Oberstraß J, Reifenberger G, Kiessling M and Cremer T. . 1996 Oncogene 13: 983–994.
Acknowledgements
PCR primers for the AKT2 gene were designed using sequence generously provided by Dr Joseph Testa (Fox Chase Cancer Center, Philadelphia, PA, USA). This work was supported by NIH grants: CA50905 (D Kimmel, J O'Fallon, BW Scheithauer, RB Jenkins), CA50910 (A Yates), CA64898 (BG Feuerstein), CA61147 (BG Feuerstein), CA64928 (PC Burger), and by The American Brain Tumor Foundation (A Perry). Justin Smith is supported by the Sidney Luckman Endowed Physician Scientist Scholarship.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Smith, J., Alderete, B., Minn, Y. et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 18, 4144–4152 (1999). https://doi.org/10.1038/sj.onc.1202759
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202759
Keywords
This article is cited by
-
Genes of the Ubiquitin Proteasome System Qualify as Differential Markers in Malignant Glioma of Astrocytic and Oligodendroglial Origin
Cellular and Molecular Neurobiology (2023)
-
Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study
Acta Neuropathologica Communications (2021)
-
In vivo Engineering of Chromosome 19 q-arm by Employing the CRISPR/AsCpf1 and ddAsCpf1 Systems in Human Malignant Gliomas (Hypothesis)
Journal of Molecular Neuroscience (2021)
-
Analysis of P78: A Novel Cytoplasmic Membrane-Associated Protein Encoded on Chromosome 19q13.3 in Glioma Specimens
Journal of Molecular Neuroscience (2020)
-
Overall survival and progression-free survival in patients with primary brain tumors after treatment: is the outcome of [18F] FDOPA PET a prognostic factor in these patients?
Annals of Nuclear Medicine (2019)